Skip to main content
SpringerLink
Log in

Anti-dementia Medications: Specific Agents

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 300 Accesses

Abstract

Dementia is a wide range of symptoms associated with a decline in cognitive functions or mental disorders severe enough to reduce a person’s ability to perform everyday activities. Pattern of impairment, course of dementia, and distinct subtypes of dementia syndromes are identifiable by using laboratory and imaging tools. Alzheimer’s disease (AD) is the most common cause of dementia, followed by vascular dementia (VaD) or mixed forms of AD and VaD. Other forms of neurodegenerative diseases (e.g. Parkinson’s disease, Lewy body disease, frontotemporal dementia) are accompanied with dementia as well. The clinical manifestation of dementia includes cognitive impairments and mental disorders. Although there is no cure for dementia, appropriate medical treatment can improve cognitive functions, mood disorders, and the living ability of patients with dementia. Accurate and early diagnosis is extremely important for dementia treatment, and early medicine intervention can effectively alleviate the symptoms of patients with dementia and improve their daily living ability and quality of life. In this chapter, we summarized the current pharmacological therapeutics of dementia, mainly the treatment of the cognitive dysfunctions and the treatment of mental behavioral symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004;17(3):164–71.

    Article  PubMed  Google Scholar 

  • Araki T, Wake R, Miyaoka T, Kawakami K, Nagahama M, Furuya M, et al. The effects of combine treatment of memantine and donepezil on Alzheimer’s disease patients and its relationship with cerebral blood flow in the prefrontal area. Int J Geriatr Psychiatry. 2014;29(9):881–9.

    Article  PubMed  Google Scholar 

  • Arciniegas DB, Anderson CA. Donepezil-induced confusional state in a patient with autopsy-proven behavioral-variant frontotemporal dementia. J Neuropsychiatr Clin Neurosci. 2013;25(3):E25–6.

    Article  Google Scholar 

  • Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5(1):6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Auriacombe S, Pere JJ, Loria-Kanza Y, Vellas B. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 2002;18(3):129–38.

    Article  CAS  PubMed  Google Scholar 

  • Ballard CG, Chalmers KA, Todd C, McKeith IG, O’Brien JT, Wilcock G, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology. 2007;68(20):1726–9.

    Article  CAS  PubMed  Google Scholar 

  • Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, et al. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer’s disease. Curr Med Res Opin. 2005;21(11):1809–18.

    Article  CAS  PubMed  Google Scholar 

  • Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007:CD003120.

    Google Scholar 

  • Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S23–8.

    Article  CAS  PubMed  Google Scholar 

  • Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer’s disease. Neurology. 1997;48(5 Suppl 6):S17–24.

    Article  CAS  PubMed  Google Scholar 

  • Boxer AL, Lipton AM, Womack K, Merrilees J, Neuhaus J, Pavlic D, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23(3):211–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, et al. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(2):149–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer’s disease over a 2-year period. Curr Med Res Opin. 2005;21(8):1317–27.

    Article  CAS  PubMed  Google Scholar 

  • Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, et al. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial. Arch Neurol. 2011;68(10):1245–51.

    Article  PubMed  Google Scholar 

  • Choi SJ, Kim MJ, Heo HJ, Kim HK, Hong B, Kim CJ, et al. Protective effect of Rosa laevigata against amyloid beta peptide-induced oxidative stress. Amyloid. 2006;13:6–12.

    Article  PubMed  Google Scholar 

  • Coca A. Hypertension and vascular dementia in the elderly: the potential role of anti-hypertensive agents. Curr Med Res Opin. 2013;29(9):1045–54.

    Article  CAS  PubMed  Google Scholar 

  • Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet. 2004;363(9427):2105–15.

    Article  CAS  PubMed  Google Scholar 

  • Cummings J, Froelich L, Black SE, Bakchine S, Bellelli G, Molinuevo JL, et al. Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm(2)) in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33(5):341–53.

    Article  CAS  PubMed  Google Scholar 

  • Curran S, Turner D, Musa S, Wattis J. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups. Int J Geriatr Psychiatry. 2005;20(9):842–7.

    Article  PubMed  Google Scholar 

  • Damar U, Gersner R, Johnstone JT, Schachter S, Rotenberg A. Huperzine A: A promising anticonvulsant, disease modifying, and memory enhancing treatment option in Alzheimer’s disease. Med Hypotheses. 2017;99:57–62.

    Article  CAS  PubMed  Google Scholar 

  • DeKosky ST, Fitzpatrick A, Ives DG, Saxton J, Williamson J, Lopez OL, et al. The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemp Clin Trials. 2006;27:238–53.

    Article  PubMed  Google Scholar 

  • Dhamoon MS, Tai W, Boden-Albala B, Rundek T, Paik MC, Sacco RL, et al. Risk of myocardial infarction or vascular death after first ischemic stroke: the Northern Manhattan Study. Stroke. 2007;38(6):1752–8.

    Article  PubMed  Google Scholar 

  • Diehl-Schmid J, Forstl H, Perneczky R, Pohl C, Kurz A. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatry. 2008;23(7):754–9.

    Article  PubMed  Google Scholar 

  • Dos Santos-Neto LL, de Vilhena Toledo MA, Medeiros-Souza P, de Souza GA. The use of herbal medicine in Alzheimer’s disease-a systematic review. Evid Based Complement Alternat Med. 2006;3:441–5.

    Article  PubMed  PubMed Central  Google Scholar 

  • Emre M. Switching cholinesterase inhibitors in patients with Alzheimer’s disease. Int J Clin Pract Suppl. 2002;127:64–72.

    CAS  Google Scholar 

  • Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzelnigg A, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(10):969–77.

    Article  CAS  PubMed  Google Scholar 

  • Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, et al. Long-term safety of rivastigmine in Parkinson disease dementia: an open-label randomized study. Clin Neuropharmacol. 2014;37(1):9–16.

    CAS  PubMed  Google Scholar 

  • Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359(9314):1283–90.

    Article  PubMed  Google Scholar 

  • Ernst E, Pittler MH. Ginkgo biloba for vascular dementia and Alzheimer’s disease: Updated systematic review of double-blind, placebo-controlled, randomized trials. Perfusion. 2005;18:388–392.

    Google Scholar 

  • Fabbrini G, Barbanti P, Bonifati V, Colosimo C, Gasparini M, Vanacore N, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103(2):123–5.

    Article  CAS  PubMed  Google Scholar 

  • Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf. 2008;31(7):577–85.

    Article  CAS  PubMed  Google Scholar 

  • Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010;32(7):1234–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia. CNS Neurosci Ther. 2013;19(10):745–52.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Frances A, Sandra O, Lucy U. Vascular cognitive impairment, a cardiovascular complication. World J Psychiatry. 2016;6(2):199–207.

    Article  PubMed  PubMed Central  Google Scholar 

  • Gauthier S, Molinuevo JL. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer’s disease. Alzheimers Dement. 2013;9(3):326–31.

    Article  PubMed  Google Scholar 

  • Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537–45.

    Article  CAS  PubMed  Google Scholar 

  • Gill SS, Bronskill SE, Normand SL, Anderson GM, Sykora K, Lam K, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775–86.

    Article  PubMed  Google Scholar 

  • Han SH, Lee JH, Kim SY, Park KW, Chen C, Tripathi M, et al. Donepezil 23 mg in Asian patients with moderate-to-severe Alzheimer’s disease. Acta Neurol Scand. 2017;135(2):252–6.

    Article  CAS  PubMed  Google Scholar 

  • Heinrich M, Lee Teoh H. Galanthamine from snowdrop–the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge. J Ethnopharmacol. 2004;92:147–62.

    Article  CAS  PubMed  Google Scholar 

  • Hellweg R, Wirth Y, Janetzky W, Hartmann S. Efficacy of memantine in delaying clinical worsening in Alzheimer’s disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD. Int J Geriatr Psychiatry. 2012;27(6):651–6.

    Article  PubMed  Google Scholar 

  • Hiraoka K, Okamura N, Funaki Y, Hayashi A, Tashiro M, Hisanaga K, et al. Cholinergic deficit and response to donepezil therapy in Parkinson’s disease with dementia. Eur Neurol. 2012;68(3):137–43.

    Article  CAS  PubMed  Google Scholar 

  • Homma A, Atarashi H, Kubota N, Nakai K, Takase T. Efficacy and safety of sustained release donepezil high dose versus immediate release donepezil standard dose in Japanese patients with severe Alzheimer’s disease: a randomized, double-blind trial. J Alzheimers Dis. 2016;52(1):345–57.

    Article  CAS  PubMed  Google Scholar 

  • Huang XT, Qian ZM, He X, Gong Q, Wu KC, Jiang LR, et al. Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer’s disease. Neurobiol Aging. 2014;35(5):1045–54.

    Article  CAS  PubMed  Google Scholar 

  • Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, et al. Impact of hypertension on cognitive function: a scientific statement from the American Heart Association. Hypertension. 2016;68(6):e67–94.

    Article  CAS  PubMed  Google Scholar 

  • Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N, et al. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013;36(3–4):229–41.

    Article  CAS  PubMed  Google Scholar 

  • Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled confirmatory phase III trial. Alzheimer’s Res Ther. 2015;7(1):4.

    Article  CAS  Google Scholar 

  • Isaacson RS, Ferris S, Velting DM, Meng X. Cognitive efficacy (SIB) of 13.3 Versus 4.6 mg/24 h rivastigmine patch in severe Alzheimer’s disease. Am J Alzheimers Dis Other Dement. 2016;31(3):270–7.

    Article  Google Scholar 

  • Ishikawa K, Motoi Y, Mizuno Y, Kubo S, Hattori N. Effects of donepezil dose escalation in Parkinson’s patients with dementia receiving long-term donepezil treatment: an exploratory study. Psychogeriatrics. 2014;14(2):93–100.

    Article  PubMed  Google Scholar 

  • Jeyapaul P, Manchip S. Management guidelines for behavioural and psychotic symptoms in persons with dementia-A review article. Open J Psychiatr. 2014;4:5–8.

    Article  Google Scholar 

  • Jia Q, Zhao X, Wang C, Wang Y, Yan Y, Li H, et al. Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry. Stroke. 2011;42(10):2758–62.

    Article  PubMed  Google Scholar 

  • Jirong Y, Xiaoyan Y, Taixiang W, Defen S, Birong D. Zhiling decoction for vascular dementia. Cochrane Database Syst Rev. 2004:CD004670.

    Google Scholar 

  • Johansson C, Ballard C, Hansson O, Palmqvist S, Minthon L, Aarsland D, et al. Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. Int J Geriatr Psychiatry. 2011;26(2):206–13.

    Article  CAS  PubMed  Google Scholar 

  • Kertesz A, Morlog D, Light M, Blair M, Davidson W, Jesso S, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178–85.

    Article  CAS  PubMed  Google Scholar 

  • Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int. 2013;13(2):506–7.

    Article  PubMed  Google Scholar 

  • Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74(11):885–92.

    Article  CAS  PubMed  Google Scholar 

  • Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol. 1989;166(3):589–90.

    Article  CAS  PubMed  Google Scholar 

  • Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206(4):297–300.

    Article  CAS  PubMed  Google Scholar 

  • Lachaine J, Beauchemin C, Legault M, Bineau S. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatr. 2011;56(10):596–604.

    Article  Google Scholar 

  • Lachaine J, Beauchemin C, Crochard A, Bineau S. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Regie de l’Assurance Maladie du Quebec database. Can J Psychiatr. 2013;58(4):195–200.

    Article  Google Scholar 

  • Larsson V, Engedal K, Aarsland D, Wattmo C, Minthon L, Londos E. Quality of life and the effect of memantine in dementia with Lewy bodies and Parkinson’s disease dementia. Dement Geriatr Cogn Disord. 2011;32(4):227–34.

    Article  CAS  PubMed  Google Scholar 

  • Liepelt I, Gaenslen A, Godau J, Di Santo A, Schweitzer KJ, Gasser T, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70–4.

    Article  CAS  PubMed  Google Scholar 

  • Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer’s disease and cognitive decline in older persons. Sleep. 2013;36(7):1027–32.

    Article  PubMed  PubMed Central  Google Scholar 

  • Lindsay J, Hebert R, Rockwood K. The Canadian study of health and aging: risk factors for vascular dementia. Stroke. 1997;28(3):526–30.

    Article  CAS  PubMed  Google Scholar 

  • Litvan I, Gomez C, Atack JR, Gillespie M, Kask AM, Mouradian MM, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989;26(3):404–7.

    Article  CAS  PubMed  Google Scholar 

  • Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467–73.

    Article  CAS  PubMed  Google Scholar 

  • Litvinenko IV, Odinak MM, Mogil’naya VI, Perstnev SV. Use of memantine (akatinol) for the correction of cognitive impairments in Parkinson’s disease complicated by dementia. Neurosci Behav Physiol. 2010;40(2):149–55.

    Article  CAS  PubMed  Google Scholar 

  • Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R, Baldacci F, et al. Levodopa response in dementia with lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010;16(8):522–6.

    Article  PubMed  Google Scholar 

  • Luchsinger JA. Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis. 2012;30(Suppl 2):S185–98.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mamikonyan E, Xie SX, Melvin E, Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord. 2015;30(7):912–8.

    Article  CAS  PubMed  Google Scholar 

  • Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer’s disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3(1)

    Article  PubMed  PubMed Central  Google Scholar 

  • Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One. 2015a;10(4):e0123289.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Matsunaga S, Kishi T, Yasue I, Iwata N. Cholinesterase inhibitors for lewy body disorders: a meta-analysis. Int J Neuropsychopharmacol. 2015b;19(2) https://doi.org/10.1093/ijnp/pyv086.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356(9247):2031–6.

    Article  CAS  PubMed  Google Scholar 

  • Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009;24(5):532–8.

    Article  PubMed  Google Scholar 

  • Mendez MF, Shapira JS, McMurtray A, Licht E. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatry. 2007;15(1):84–7.

    Article  PubMed  Google Scholar 

  • Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2003;18(11):988–93.

    Article  PubMed  Google Scholar 

  • Molinuevo JL, Berthier ML, Rami L. Donepezil provides greater benefits in mild compared to moderate Alzheimer’s disease: implications for early diagnosis and treatment. Arch Gerontol Geriatr. 2011;52(1):18–22.

    Article  CAS  PubMed  Google Scholar 

  • Moretti R, Torre P, Antonello RM, Cattaruzza T, Cazzato G, Bava A. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21(14):931–7.

    Article  CAS  PubMed  Google Scholar 

  • Mori E, Ikeda M, Kosaka K, Donepezil DLBSI. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41–52.

    Article  CAS  PubMed  Google Scholar 

  • Mori E, Ikeda M, Nagai R, Matsuo K, Nakagawa M, Kosaka K. Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial. Alzheimers Res Ther. 2015a;7(1):5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Mori E, Ikeda M, Nakagawa M, Miyagishi H, Yamaguchi H, Kosaka K. Effects of donepezil on extrapyramidal symptoms in patients with dementia with lewy bodies: a secondary pooled analysis of two randomized-controlled and two open-label long-term extension studies. Dement Geriatr Cogn Disord. 2015b;40(3–4):186–98.

    Article  CAS  PubMed  Google Scholar 

  • Moroney JT, Bagiella E, Desmond DW, Paik MC, Stern Y, Tatemichi TK. Risk factors for incident dementia after stroke. Role of hypoxic and ischemic disorders. Stroke. 1996;27(8):1283–9.

    Article  CAS  PubMed  Google Scholar 

  • Nakamura Y, Imai Y, Shigeta M, Graf A, Shirahase T, Kim H, et al. A 24-week, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of the rivastigmine patch in Japanese patients with Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2011;1(1):163–79.

    Article  PubMed  PubMed Central  Google Scholar 

  • Nakamura Y, Kitamura S, Homma A, Shiosakai K, Matsui D. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opin Pharmacother. 2014;15(7):913–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nebes RD, Buysse DJ, Halligan EM, Houck PR, Monk TH. Self-reported sleep quality predicts poor cognitive performance in healthy older adults. J Gerontol B Psychol Sci Soc Sci. 2009;64(2):180–7.

    Article  PubMed  Google Scholar 

  • O’Brien JT, Thomas A. Vascular dementia. Lancet. 2015;386(10004):1698–706.

    Article  PubMed  Google Scholar 

  • O’Brien JT, Burns A, Group BAPDC. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2011;25(8):997–1019.

    Article  PubMed  CAS  Google Scholar 

  • Oertel W, Poewe W, Wolters E, De Deyn PP, Emre M, Kirsch C, et al. Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson’s disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf. 2008;31(1):79–94.

    Article  CAS  PubMed  Google Scholar 

  • Oh YS, Kim JS, Ryu DW, Lee KS. Donepezil induced antecollis in a patient with Parkinson’s disease dementia. Neurol Sci. 2013;34(9):1685–6.

    Article  PubMed  Google Scholar 

  • Olin J, Schneider L, Novit A, Luczak S. Hydergine for dementia. Cochrane Database Syst Rev. 2001;2:CD000359.

    Google Scholar 

  • Onofrj M, Varanese S, Bonanni L, Taylor JP, Antonini A, Valente EM, et al. Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. J Neurol. 2013;260(7):1731–42.

    Article  PubMed  PubMed Central  Google Scholar 

  • Park SY, Kim DS. Discovery of natural products from Curcuma longa that protect cells from beta-amyloid insult: a drug discovery effort against Alzheimer’s disease. J Nat Prod. 2002;65:1227–31.

    Article  CAS  PubMed  Google Scholar 

  • Putaala J, Haapaniemi E, Kaste M, Tatlisumak T. Statins after ischemic stroke of undetermined etiology in young adults. Neurology. 2011;77(5):426–30.

    Article  CAS  PubMed  Google Scholar 

  • Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A, et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry. 2005;76(7):934–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–41.

    Article  CAS  PubMed  Google Scholar 

  • Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology. 2005;65(3):481–2.

    Article  CAS  PubMed  Google Scholar 

  • Riederer P, Korczyn AD, Ali SS, Bajenaru O, Choi MS, Chopp M, et al. The diabetic brain and cognition. J Neural Transm (Vienna). 2017;124(11):1431–54.

    Article  Google Scholar 

  • Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev. 2012;3:CD006504.

    Google Scholar 

  • Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ. 1999;318(7184):633–8.

    Article  PubMed  PubMed Central  Google Scholar 

  • Rossom R, Adityanjee A, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother. 2004;2(4):303–12.

    Article  CAS  PubMed  Google Scholar 

  • Rothman SM, Herdener N, Frankola KA, Mughal MR, Mattson MP. Chronic mild sleep restriction accentuates contextual memory impairments, and accumulations of cortical Abeta and pTau in a mouse model of Alzheimer’s disease. Brain Res. 2013;1529:200–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sadowsky CH, Micca JL, Grossberg GT, Velting DM. Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer’s disease and Parkinson’s disease dementia. Prim Care Comp CNS Disord. 2014;16(5) https://doi.org/10.4088/PCC.14r01654.

  • Schlosser Covell GE, Dhawan PS, Lee Iannotti JK, Hoffman-Snyder CR, Wellik KE, Caselli RJ, et al. Disrupted daytime activity and altered sleep-wake patterns may predict transition to mild cognitive impairment or dementia: a critically appraised topic. Neurologist. 2012;18(6):426–9.

    Article  PubMed  Google Scholar 

  • Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T, et al. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol. 2015;22(6):889–98.

    Article  CAS  PubMed  Google Scholar 

  • Schmitt FA, Aarsland D, Bronnick KS, Meng X, Tekin S, Olin JT. Evaluating rivastigmine in mild-to-moderate Parkinson’s disease dementia using ADAS-cog items. Am J Alzheimers Dis Other Dement. 2010a;25(5):407–13.

    Article  Google Scholar 

  • Schmitt FA, Farlow MR, Meng X, Tekin S, Olin JT. Efficacy of rivastigmine on executive function in patients with Parkinson’s disease dementia. CNS Neurosci Ther. 2010b;16(6):330–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61(12):1852–6.

    Article  PubMed  Google Scholar 

  • Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–80.

    Article  PubMed  PubMed Central  Google Scholar 

  • Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73(4):273–8.

    Article  CAS  PubMed  Google Scholar 

  • Shimada H, Hirano S, Sinotoh H, Ota T, Tanaka N, Sato K, et al. Dementia with Lewy bodies can be well-differentiated from Alzheimer’s disease by measurement of brain acetylcholinesterase activity-a [11C]MP4A PET study. Int J Geriatr Psychiatry. 2015;30(11):1105–13.

    Article  CAS  PubMed  Google Scholar 

  • Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia – a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry. 2002;17(6):579–85.

    Article  PubMed  Google Scholar 

  • Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002;288:835–40.

    Article  PubMed  Google Scholar 

  • Stahl SM, Markowitz JS, Gutterman EM, Papadopoulos G. Co-use of donepezil and hypnotics among Alzheimer’s disease patients living in the community. J Clin Psychiatry. 2003;64(4):466–72.

    Article  CAS  PubMed  Google Scholar 

  • Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169(9):900–6.

    Article  PubMed  PubMed Central  Google Scholar 

  • Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry. 2005;66(Suppl 2):9–13.

    CAS  PubMed  Google Scholar 

  • Stubendorff K, Larsson V, Ballard C, Minthon L, Aarsland D, Londos E. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: a prospective study. BMJ Open. 2014;4(7):e005158.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, et al. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014;41(2):615–31.

    Article  CAS  PubMed  Google Scholar 

  • Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.

    Article  CAS  PubMed  Google Scholar 

  • Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology. 2000;55(9):1271–8.

    Article  CAS  PubMed  Google Scholar 

  • Thompson S, Herrmann N, Rapoport MJ, Lanctot KL. Efficacy and safety of antidepressants for treatment of depression in Alzheimer’s disease: a meta-analysis. Can J Psychiatr. 2007;52(4):248–55.

    Article  Google Scholar 

  • Van Puyvelde K, Mets T, RODOS Study Group. Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer’s disease: a study in a real life population. Geriatr Gerontol Int. 2011;11(3):256–61.

    Article  PubMed  Google Scholar 

  • Vercelletto M, Boutoleau-Bretonniere C, Volteau C, Puel M, Auriacombe S, Sarazin M, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimers Dis. 2011;23(4):749–59.

    Article  PubMed  Google Scholar 

  • Vidal EI, Fukushima FB, Valle AP, Villas Boas PJ. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson’s disease dementia. J Am Geriatr Soc. 2013;61(1):170–2.

    Article  PubMed  Google Scholar 

  • Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin. 2006;27:1–26.

    Article  PubMed  CAS  Google Scholar 

  • Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015;86(2):135–43.

    Article  PubMed  Google Scholar 

  • Weintraub D, Somogyi M, Meng X. Rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia: an ADAS-cog factor analysis. Am J Alzheimers Dis Other Dement. 2011;26(6):443–9.

    Article  Google Scholar 

  • Wesnes KA, Aarsland D, Ballard C, Londos E. Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2015;30(1):46–54.

    Article  PubMed  Google Scholar 

  • Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004;19(7):624–33.

    Article  PubMed  Google Scholar 

  • Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer’s disease. Dement Geriatr Cogn Disord. 2007;24(2):138–45.

    Article  CAS  PubMed  Google Scholar 

  • Wilkinson DG, Passmore AP, Bullock R, Hopker SW, Smith R, Potocnik FC, et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer’s disease. Int J Clin Pract. 2002;56(6):441–6.

    CAS  PubMed  Google Scholar 

  • Wilkinson D, Wirth Y, Goebel C. Memantine in patients with moderate to severe Alzheimer’s disease: meta-analyses using realistic definitions of response. Dement Geriatr Cogn Disord. 2014;37(1–2):71–85.

    Article  CAS  PubMed  Google Scholar 

  • Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456–67.

    Article  PubMed  Google Scholar 

  • Winblad B, Gauthier S, Astrom D, Stender K. Memantine benefits functional abilities in moderate to severe Alzheimer’s disease. J Nutr Health Aging. 2010;14(9):770–4.

    Article  CAS  PubMed  Google Scholar 

  • Yang G, Wang Y, Tian J, Liu JP. Huperzine A for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One. 2013a;8(9):e74916.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yang Z, Zhou X, Zhang Q. Effectiveness and safety of memantine treatment for Alzheimer’s disease. J Alzheimers Dis. 2013b;36(3):445–58.

    Article  CAS  PubMed  Google Scholar 

  • Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease. Pharmacol Biochem Behav. 2003;75:675–86.

    Article  CAS  PubMed  Google Scholar 

  • Zavoreo I, Madzar Z, Demarin V, Kes VB. Vascular cognitive impairment in diabetes mellitus: are prevention and treatment effective? Acta Clin Croat. 2014;53(3):326–33.

    PubMed  Google Scholar 

  • Zhou H, Yang J, Xie P, Dong Y, You Y, Liu J. Cerebral microbleeds, cognitive impairment, and MRI in patients with diabetes mellitus. Clin Chim Acta. 2017;470:14–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Feng Zhang, Xinyao Liu and Yufei Liu contributed equally with all other contributors.

Authors and Affiliations

  1. The First Affiliated Hospital, Dalian Medical University, Dalian, China

    Feng Zhang, Xinyao Liu, Yufei Liu & Weidong Le

  2. Daping Hospital, Third Military Medical University, Chongqing, China

    Yanjiang Wang

Authors
  1. Feng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinyao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yufei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanjiang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Weidong Le
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Weidong Le .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. Szeged, Hungary

    Laszlo Vecsei

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Zhang, F., Liu, X., Liu, Y., Wang, Y., Le, W. (2020). Anti-dementia Medications: Specific Agents. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_283-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_283-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation